Concepedia

Luis Fayad

LF

20

Publications

1.7K

Citations

15

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Lymphoma Research Foundation

Memorial Sloan Kettering Cancer Center

Mary Crowley Cancer Research Center

Ionis Pharmaceuticals (United States)

Luis Fayad is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and immunology.

Top concepts

Publications per year

1999–2022

20

Publications

20

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 428 citations · Full text

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

Luis Fayad, Michael J. Keating, James M. Reuben et al. · Blood · 2001 · 287 citations · Full text

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook et al. · Journal for ImmunoTherapy of Cancer · 2018 · 275 citations · Full text

Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas

Issa F. Khouri, Rima M. Saliba, Chitra Hosing et al. · Journal of Clinical Oncology · 2005 · 129 citations

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Preetesh Jain, Rashmi Kanagal‐Shamanna, Shaojun Zhang et al. · British Journal of Haematology · 2018 · 111 citations · Full text

Rows per page

1–5 of 20